15 Stocks ChatGPT Predicts Could Make You Wealthy in 10 Years

9. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders: 81

Johnson & Johnson (NYSE:JNJ) is a New Jersey-based multinational corporation, engaged in the research and development, and sale of a variety of healthcare products that serve over 52 million patients across 103 countries every day.

Over the last few years, the company has been shifting its focus from consumer health products toward the pharmaceuticals and medtech sectors, which offer significant opportunities for growth. On January 13, Johnson & Johnson (NYSE:JNJ) announced the acquisition of neurological drugmaker, Intra-Cellular, for $14.6 billion, through which the company will gain access to Caplyta, an oral drug to treat schizophrenia and bipolar disorder. The deal is part of a string of recent acquisitions by Johnson & Johnson (NYSE:JNJ) as it looks to drive growth in 2025 and beyond. In 2024, it acquired Proteologix, a biotech company focused on bispecific antibodies for immune-mediated diseases, for $850 million. During the same year, it bought the rights to Numab’s skin disorder drug for $1.25 billion. It also acquired heart device maker, Shockwave Medical, for $13.1 billion, bolstering the growth potential of its medical device business.

On January 22, Johnson & Johnson (NYSE:JNJ) reported financial results for the fourth quarter and full year 2024. It beat quarterly estimates for both revenue and profits, driven by strong sales of its cancer treatments. For the full year, the company posted sales of $88.8 billion, growing 4.3% year-over-year. Adjusted EPS stood at $9.98 per share. The strong results reflected the strength of JNJ’s high-growth strategy.

Wall Street analysts are bullish on Johnson & Johnson (NYSE:JNJ) with a consensus Buy rating and an average share price upside potential of over 21%. It is among the stocks ChatGPT predicts could make you wealthy in 10 years.